SCHEMBL1661412

SCHEMBL1661412

CN1C=Cc2ccccc2O1

nearest known ligand 0.34

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.34
CCL2 P13500 1/20 0.34
MEN1 O00255 2/20 0.33
MAPT P10636 2/20 0.33
KMT2A Q03164 2/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HTR2C P28335 1/20 0.33
HTR2B P41595 1/20 0.33
TP53 P04637 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
UBE2N P61088 1/20 0.33
DRD2 P14416 1/20 0.31
DRD4 P21917 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15201897 0.75 HTR2C (0.32) MEN1MAPTKMT2AKDM4EALDH1A1
SCHEMBL22115886 0.74 KDM4E (0.33) MEN1MAPTKMT2AKDM4EALDH1A1
SCHEMBL5494922 0.74 KDM4E (0.33) MEN1MAPTKMT2AKDM4EALDH1A1
SCHEMBL3342528 0.74 KDM4E (0.37) MEN1MAPTKMT2AKDM4EALDH1A1
SCHEMBL3235007 0.74 KDM4E (0.33) MEN1MAPTKMT2AKDM4EALDH1A1
SCHEMBL1491181 0.74 KDM4E (0.33) MEN1MAPTKMT2AKDM4EALDH1A1
SCHEMBL23346752 0.74 HTR2C (0.31) MEN1MAPTKMT2AKDM4EALDH1A1
SCHEMBL23346683 0.72 CA12 (0.42) MEN1MAPTKMT2AKDM4EALDH1A1
SCHEMBL23346689 0.72 KDM4E (0.44) MEN1MAPTKMT2AKDM4EALDH1A1
SCHEMBL253209 0.71 ALDH1A1 (0.39) MEN1MAPTKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4282358-A CYCLIZATION OF 2-HALOPHENOXYANILINES CIBA-GEIGY CORPORATION (US) 1981-08-04 US claimed
CN-115611821-B Low-dielectric and high-heat-resistance aza calixarene resin, and preparation method and application thereof 山东大学 2024-03-26 CN disclosed
EP-4272832-A2 ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF Lakewood Amedex, Inc. (US) 2023-11-08 EP disclosed
CN-115611821-A Low dielectric and high heat-resistant azacalixarene resin and preparation method and application thereof 山东大学 2023-01-17 CN disclosed
US-9249087-B2 HDAC inhibitors and therapeutic methods using the same THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2016-02-02 US disclosed
US-20140128408-A1 HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2014-05-08 US disclosed
EP-2314579-A1 Fast-curing benzoxazine compounds Henkel AG & Co. KGaA (DE) 2011-04-27 EP disclosed
US-7112584-B2 Nonsteroidal antiinflammatory agents SCHERING AG (DE) 2006-09-26 US disclosed
EP-1182238-B1 Ink jet printing method EASTMAN KODAK CO (US) 2005-01-05 EP disclosed
US-20040209875-A1 Nonsteroidal antiinflammatory agents SCHERIN AKTIENGESELLSCHAFT (DE) 2004-10-21 US disclosed
US-6419354-B1 PRINTING IN RESPONSE TO DIGITAL SIGNALS EASTMAN KODAK COMPANY 2002-07-16 US disclosed
EP-1182240-A2 Ink jet ink composition EASTMAN KODAK COMPANY (US) 2002-02-27 EP disclosed
EP-1182239-A2 Ink Jet Ink composition EASTMAN KODAK COMPANY (US) 2002-02-27 EP disclosed
EP-1182238-A1 Ink jet printing method EASTMAN KODAK COMPANY (US) 2002-02-27 EP disclosed
EP-1182050-A2 Ink jet printing method EASTMAN KODAK COMPANY (US) 2002-02-27 EP disclosed
EP-0368410-A2 Optically active benzoxazines and bezothiazines and a process for their stereospecific preparation GIST-BROCADES N.V. (NL) 1990-05-16 EP disclosed
US-4282358-A CYCLIZATION OF 2-HALOPHENOXYANILINES CIBA-GEIGY CORPORATION (US) 1981-08-04 US disclosed
US-4282358-A CYCLIZATION OF 2-HALOPHENOXYANILINES CIBA-GEIGY CORPORATION (US) 1981-08-04 US disclosed
US-4282358-A CYCLIZATION OF 2-HALOPHENOXYANILINES CIBA-GEIGY CORPORATION (US) 1981-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140128408-A1 HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME HDAC1, HDAC9, HDAC8 BRD4 184/4885CCL2 3704/4885MEN1 1417/4885
US-20040209875-A1 Nonsteroidal antiinflammatory agents PTGS1, PTGER1, PTGES BRD4 3166/4885CCL2 178/4885MEN1 1721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.